# Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

> **NCT01514149** · PHASE2 · TERMINATED · sponsor: **ConjuChem** · enrollment: 73 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** CJC-1134-PC Injection
- **DRUG:** Weekly placebo for CJC-1134-PC Injection

## Key facts

- **NCT ID:** NCT01514149
- **Lead sponsor:** ConjuChem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2012-05
- **Final completion:** 2013-03
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2017-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514149, "Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01514149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*